Page 1

Cantargia INTERIM REPORT January - June 2021 Unique results lay a foundation for next steps SECOND QUARTER Significant events in the second quarter ● ● ● Net sales : SEK 0 ( 0 ) million Operating loss : SEK -86.6 ( -37.7 ) million Loss after tax : SEK -85.9 ( -37.1 ) million Loss per share : before and after dilution , SEK -0.86 ( -0.41 ) ● Preclinical results for the CAN 10 antibody were presented at the IMMUNOLOGY2021 conference A letter of intent was signed with GEICAM to conduct a clinical study with nadunolimab in combination with chemotherapy in triple negative breast cancer Positive interim results were presented from the CANFOUR study showing an improved progression - free survival and overall survival for combination treatment with nadunolimab and chemotherapy in pancreatic cancer , compared to historical control data Regulatory approval was obtained to initiate the phase lb study CAPAFOUR with nadunolimab in combination with the FOLFIRINOX chemotherapy regimen in pancreatic cancer An application was submitted to start the clinical phase I / II study CESTAFOUR with nadunolimab in combination with chemotherapy in three different forms of cancer Significant events after the end of the period An application was submitted to start the clinical phase Ib / ll study TRIFOUR with nadunolimab in combination with carboplatin / gemcitabine in triple negative breast cancer Cantargia AB | 556791-6019 | INTERIM REPORT January - June 2021 HALF - YEAR ● ● ● Net sales : SEK 0 ( 0 ) million Operating loss : SEK -159.8 ( -77.6 ) million Loss after tax : SEK -158.5 ( -77.0 ) million Loss per share : before and after dilution , SEK -1.58 ( -0.89 ) Equity / assets ratio : 91 ( 93 ) per cent Cash and cash equivalents : SEK 94.7 ( 248.3 ) million Short - term investments : SEK 666.0 ( 210.0 ) million Comments on significant events The CAN 10 project has made progress and new preclinical results were presented at the IMMUNOLOGY2021 conference organized by the American Association of Immunologists . The results showed that CAN10 reduced inflammation and fibrosis in a model of myocarditis and the deterioration in cardiac function . Cantargia intends to broaden the development of nadunolimab to cover additional cancer types . As part of this effort , a letter of intent was signed with the Spanish Breast Cancer Group ( GEICAM ) to conduct a clinical phase Ib / Il study , TRIFOUR , in which nadunolimab will be evaluated with carboplatin / gemcitabine in patients with triple negative breast cancer . After an initial safety phase , the second part of the study will be conducted against a control group . The application to start TRIFOUR was submitted at the beginning of July . An application was also submitted to start the phase I / II study CESTAFOUR , where nadunolimab will be evaluated in combination with chemotherapy in three different forms of cancer . Additional positive interim results were presented from the CANFOUR study , where treatment with nadunolimab and gemcitabine / nab - paclitaxel is evaluated in pancreatic cancer patients . The results are strong compared to historical control data for chemotherapy alone and show durable responses , among other effects , as well as five patients with pseudo progression , an unusual observation in pancreatic cancer . Overall , this resulted in progression - free survival of 7.8 months and overall survival of 12.6 months . During the period , regulatory approval was obtained for a further clinical study in pancreatic cancer , CAPAFOUR , where nadunolimab will be evaluated in combination with the FOLFIRINOX chemotherapy regimen . PAGE 1